Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294784" target="_blank" >RIV/00216208:11110/15:10294784 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10294784

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ene.12618" target="_blank" >http://dx.doi.org/10.1111/ene.12618</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ene.12618" target="_blank" >10.1111/ene.12618</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

Popis výsledku v původním jazyce

Background and purposeImpaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing-remitting multiple sclerosis, could impact ambulation performance was examined. MethodsA prospective open-label study, TIMER, was conducted in natalizumab-naive patients (n=215). The timed 25-foot walk (T25FW) and timed 100-m walk (T100MW) were assessed at baseline and at weeks 24and 48 of natalizumab therapy, together with Expanded Disability Status Scale scores. The effects of natalizumab on T25FW performance were also examined in a retrospective analysis of natalizumab-treated patients (n=627) and placebo control patients (n=315) from the AFFIRM study. ResultsIn TIMER, a significant increase from baseline in T25FW speed was seen at week 24 (P=0.0074) and in T100MW speed at weeks 24 and 48 (both P<0.001). A greater proportion of patients showed clinically mean

Název v anglickém jazyce

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

Popis výsledku anglicky

Background and purposeImpaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing-remitting multiple sclerosis, could impact ambulation performance was examined. MethodsA prospective open-label study, TIMER, was conducted in natalizumab-naive patients (n=215). The timed 25-foot walk (T25FW) and timed 100-m walk (T100MW) were assessed at baseline and at weeks 24and 48 of natalizumab therapy, together with Expanded Disability Status Scale scores. The effects of natalizumab on T25FW performance were also examined in a retrospective analysis of natalizumab-treated patients (n=627) and placebo control patients (n=315) from the AFFIRM study. ResultsIn TIMER, a significant increase from baseline in T25FW speed was seen at week 24 (P=0.0074) and in T100MW speed at weeks 24 and 48 (both P<0.001). A greater proportion of patients showed clinically mean

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Neurology

ISSN

1351-5101

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

570-577

Kód UT WoS článku

000349676000023

EID výsledku v databázi Scopus

2-s2.0-84922727144